Is TG Therapeutics, Inc. (NASDAQ:TGTX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating TG Therapeutics, Inc. at current levels.
BRIUMVI is becoming the default subcutaneous anti-CD20 for MS, and the market still prices it like a one-product also-ran.
Where TGTX is headed
By mid-2028, BRIUMVI is no longer the third anti-CD20 in multiple sclerosis. It is the convenience option. A one-hour infusion already beat Ocrevus on chair time, and the subcutaneous formulation in development takes the conversation from infusion suites to home administration. That matters because MS patients on anti-CD20s are not occasional users, they are lifers. Switch costs are real, but so is the slow grind of new patient starts choosing the path of least resistance. BRIUMVI did roughly $560m in 2025 net product revenue, up from $330m the year before. A $1.2 to $1.5 billion run-rate by late 2027 is not a stretch, it is the trajectory the prescription data already shows.
Read the full Compass Direction on TGTX
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $38.87).
See the full TGTX analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is TG Therapeutics, Inc. (NASDAQ:TGTX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating TG Therapeutics, Inc. at current levels. BRIUMVI is becoming the default subcutaneous anti-CD20 for MS, and the market still prices it like a one-product also-ran.
What is TGTX's Compass Score?
TG Therapeutics, Inc. scores 90/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for TGTX?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the TGTX page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.